Jennifer Gilbert1, Robert Schnoll2, Mary F Morrison3, Sindhu K Srinivas4, Timothy Pond1, Brenda Curtis5, Jennifer Henry3, Henry R Kranzler6. 1. Treatment Research Center, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104. 2. Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104. 3. Department of Psychiatry, Temple University School of Medicine, Philadelphia, PA 19125. 4. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104. 5. Treatment Research Institute, Philadelphia, PA 19106. 6. Treatment Research Center, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Philadelphia VAMC, Philadelphia, PA 19104.
Abstract
OBJECTIVES: Although smoking during pregnancy is associated with poor pregnancy outcomes, many women continue to smoke throughout pregnancy. Behavioral interventions for smoking cessation yield modest benefits, particularly in lower socioeconomic groups. Pharmacotherapy, a first-line option for smoking cessation, has not shown clear benefits for pregnant smokers, partly due to limited adherence. We evaluated the feasibility of conducting a pharmacotherapy trial for smoking cessation in pregnant women, using text messaging to enhance medication adherence. METHODS: We surveyed 724 predominantly minority pregnant women to examine the prevalence and correlates of smoking and the use of cellular telephones and text messaging. RESULTS: Nearly 18% of the respondents were current smokers, with a majority (67.7%) expressing interest in participating in a smoking cessation trial. Only about 6% of women with a smoking history ever received nicotine dependence treatment. Smokers were significantly more likely to be depressed than non-smokers. The vast majority of respondents (92.1%) owned cell phones, with 93.2% having an unlimited text-messaging plan. CONCLUSIONS: These data support the feasibility of conducting a pharmacotherapy smoking cessation trial and using text messaging to enhance medication adherence in a predominantly minority population of pregnant smokers.
OBJECTIVES: Although smoking during pregnancy is associated with poor pregnancy outcomes, many women continue to smoke throughout pregnancy. Behavioral interventions for smoking cessation yield modest benefits, particularly in lower socioeconomic groups. Pharmacotherapy, a first-line option for smoking cessation, has not shown clear benefits for pregnant smokers, partly due to limited adherence. We evaluated the feasibility of conducting a pharmacotherapy trial for smoking cessation in pregnant women, using text messaging to enhance medication adherence. METHODS: We surveyed 724 predominantly minority pregnant women to examine the prevalence and correlates of smoking and the use of cellular telephones and text messaging. RESULTS: Nearly 18% of the respondents were current smokers, with a majority (67.7%) expressing interest in participating in a smoking cessation trial. Only about 6% of women with a smoking history ever received nicotine dependence treatment. Smokers were significantly more likely to be depressed than non-smokers. The vast majority of respondents (92.1%) owned cell phones, with 93.2% having an unlimited text-messaging plan. CONCLUSIONS: These data support the feasibility of conducting a pharmacotherapy smoking cessation trial and using text messaging to enhance medication adherence in a predominantly minority population of pregnant smokers.
Entities:
Keywords:
Cellular telephone use; Pharmacotherapy trial; Smoking during pregnancy; Text messaging; depression
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Paul M Cinciripini; David W Wetter; Rachel T Fouladi; Janice A Blalock; Brian L Carter; Lynn G Cinciripini; Walter F Baile Journal: J Consult Clin Psychol Date: 2003-04